var data={"title":"Caffeine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Caffeine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5782?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=caffeine-drug-information\" class=\"drug drug_general\">see &quot;Caffeine: Drug information&quot;</a> and <a href=\"topic.htm?path=caffeine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Caffeine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144010\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cafcit;</li>\n      <li>Keep Alert [OTC];</li>\n      <li>No Doz Maximum Strength [OTC];</li>\n      <li>Stay Awake Maximum Strength [OTC];</li>\n      <li>Stay Awake [OTC];</li>\n      <li>Vivarin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057049\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Central Nervous System Stimulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diuretic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Respiratory Stimulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442160\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Apnea of prematurity:</b> <b>Caffeine citrate: Note:</b> Dose expressed as caffeine citrate; caffeine base is <sup>1</sup>/<sub>2</sub> the dose of the caffeine citrate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> GA &ge;28 weeks and &lt;33 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: IV: 20 mg/kg caffeine citrate as a one-time dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Oral, IV: 5 mg/kg/dose caffeine citrate once daily, beginning 24 hours after loading dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing: </i>GA &lt;32 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: IV: 20 to 40 mg/kg caffeine citrate (Mohammed 2015; Schmidt 2006); loading doses as high as 80 mg/kg of caffeine citrate have been reported (Gray 2011; Steer 2004), but should be utilized with caution (See <b>Note</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Oral, IV: 5 to 20 mg/kg/dose caffeine citrate once daily starting 24 hours after the loading dose (Gray 2011; Mohammed 2015; Schmidt 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>Higher doses (Load: 40 mg/kg and 80 mg/kg; maintenance dose: 20 mg/kg/dose) were shown to significantly decrease the incidence of apnea, need for oxygen therapy, and extubation failures; incidence of tachycardia was conflicting with one study showing an increased incidence with higher doses compared to low dose (23% vs 8%) while the other showed no significant difference between low and high dose (Mohammed 2015; Steer 2004). Loading doses of 80 mg/kg must be used with caution; one study evaluating the prophylactic use of high-dose caffeine (total dose of 80 mg/kg over 36 hours) compared to standard dose showed patients in the high-dose group had a higher incidence of cerebellar hemorrhage (36% vs 10%) along with increased tone and abnormal movements (McPherson 2015); although not statistically significant, these patients also trended towards a higher incidence of seizures and increased EEG measured seizure duration over the first 72 hours; however, there was no difference in the number of clinical seizures requiring treatment, status epilepticus, IVH, hypoglycemia, or perinatal hypoxic ischemia between the 2 groups (Vesoulis 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057043\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=caffeine-drug-information\" class=\"drug drug_general\">see &quot;Caffeine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation. Caffeine and sodium benzoate dosing presented as the combination (caffeine base amount is 50% of the caffeine and sodium benzoate combination).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Stimulant: </b>OTC labeling: Caffeine (base): Children &ge;12 years and Adolescents: Oral: 100 to 200 mg every 3 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postdural puncture headache:</b> <b>Caffeine sodium benzoate:</b> IV: 500 mg (equivalent to 250 mg caffeine base) in 1,000 mL NS infused over 1 hour, followed by 1,000 mL NS infused over 2 hours; after 4 hours, a second course of caffeine can be given for unrelieved headache pain (Choi 1996; Jarvis 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stimulant:</b> OTC labeling: Caffeine (base): Oral: 100 to 200 mg every 3 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143990\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution, as citrate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [with sodium benzoate]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Caffeine 125 mg/mL and sodium benzoate 125 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, oral, as citrate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cafcit: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/3 mL (3 mL) [equivalent to 10 mg/mL caffeine base]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keep Alert: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NoDoz Maximum Strength: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stay Awake: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stay Awake Maximum Strength: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vivarin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143978\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Tablet, caffeine and sodium benzoate injection, injection, oral solution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057054\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to feedings or meals; may administer injectable formulation (caffeine citrate) orally</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caffeine citrate:</b> IV: May administer undiluted or further diluted with D5W. Infuse loading dose over at least 30 minutes; maintenance dose may be infused over at least 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caffeine sodium benzoate:</b> IV: <b>Note:</b> Use a 0.22-micron in-line filter when administering (American Regent 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Direct injection: Administer slowly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spinal headaches: Further dilute and infuse over 1 hour; follow with 1,000 mL NS infused over 2 hours (Choi 1996; Jarvis 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144007\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Caffeine citrate: Injection and oral solution contain no preservatives; injection is chemically stable for at least 24 hours at room temperature when diluted to 10 mg/mL (as caffeine citrate) with D<sub>5</sub>W, D<sub>50</sub>W, Intralipid&reg; 20%, and Aminosyn&reg; 8.5%; also compatible with dopamine (600 mcg/mL), calcium gluconate 10%, heparin (1 unit/mL), and fentanyl (10 mcg/mL) at room temperature for 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057053\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine citrate: Treatment of apnea of prematurity (FDA approved in infants with GA 28 to &lt;33 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine (base): Restore mental alertness or wakefulness when experiencing fatigue (OTC Product: FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and sodium benzoate: Treatment (in conjunction with supportive measures) of acute respiratory depression associated with overdose of CNS depressant drugs (not a preferred agent) (FDA approved in adults); has also been used for treatment of postdural puncture headaches</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144035\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Primarily serum-concentration related. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Angina pectoris, chest pain, flushing, palpitations, sinus tachycardia, supraventricular tachycardia, vasodilatation, ventricular arrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, delirium, dizziness, hallucination, headache, insomnia, irritability, psychosis, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Esophageal motility disorder (sphincter tone decreased), gastritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Diuresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Increased intraocular pressure (&gt;180 mg caffeine), miosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143996\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to caffeine or any component of the formulation; sodium benzoate is not for use in neonates</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143981\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anxiety: Avoid use in patients with anxiety, agitation, or tremor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; avoid use in patients with symptomatic cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of peptic ulcer and/or gastroesophageal reflux.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Caffeine citrate should be closely monitored for the development of necrotizing enterocolitis in the neonate; caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity. Avoid use of products containing sodium benzoate in neonates; has been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates, including metabolic acidosis, respiratory distress, gasping respirations, seizures, intracranial hemorrhage, hypotension, and cardiovascular collapse. <i>In vitro</i> and animal studies have shown that benzoate also displaces bilirubin from protein-binding sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC products: OTC products contain 200 mg of caffeine per tablet approximately the amount of caffeine similar to one cup of coffee; limit the use of other caffeine-containing beverages or foods.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: <b>Caffeine citrate should not be interchanged with caffeine and sodium benzoate.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transcutaneous electrical nerve stimulation: Analgesia from transcutaneous electrical nerve stimulation may be lessened with concomitant caffeine use (Marchand 1995).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855220\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">During a caffeine citrate double-blind, placebo-controlled study, six of 85 patients developed necrotizing enterocolitis (NEC); five of these six patients had received caffeine citrate; although no causal relationship has been established, neonates who receive caffeine citrate should be closely monitored for the development of NEC. Caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The incidence of cerebellar hemorrhage was shown to be increased in patients receiving high-dose caffeine citrate (80 mg/kg total load over 36 hours) compared to those receiving standard doses (36% vs 10%) in a randomized, controlled trial in preterm neonates (n=74; GA &le;30 weeks; PNA &le;24 hours); in addition, this group also had subtle neurobehavioral differences including increased tone and abnormal movements at term equivalent age (McPherson 2015). In a post hoc analysis of this same group of neonates the high-dose group also trended towards a higher incidence of seizures (40% vs 58%; p = 0.1) and an increase in seizure duration (48.9 vs 170.9 seconds; p = 0.1) as indicated by continuous limited channel aEEG monitoring over the first 72 hours of life, although this was not statistically significant. No difference in the number of clinical seizures requiring treatment or status epilepticus were noted between the groups; also no difference in the rates of IVH, hypoglycemia or perinatal hypoxic ischemia were noted (Vesoulis 2016). Authors noted that these adverse effects discouraged the potential for a larger trial; if use deemed necessary, close monitoring is recommended (McPherson 2015; Vesoulis 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144025\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143985\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13360&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Caffeine and Caffeine Containing Products may diminish the therapeutic effect of Adenosine.  Management: Monitor for decreased effect of adenosine if patient is receiving caffeine. Discontinue caffeine in advance of scheduled diagnostic use of adenosine whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Caffeine and Caffeine Containing Products may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Caffeine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Indacaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Caffeine and Caffeine Containing Products may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norfloxacin: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olodaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pipemidic Acid: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regadenoson: Caffeine and Caffeine Containing Products may diminish the vasodilatory effect of Regadenoson.  Management: Avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of Caffeine and Caffeine Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143987\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143998\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Caffeine crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Grosso 2005). Based on current studies, usual dietary exposure to caffeine is unlikely to cause congenital malformations (Brent 2011). However, available data shows conflicting results related to maternal caffeine use and the risk of other adverse events, such as spontaneous abortion or growth retardation (Brent 2011; Jahanfar 2013). The half-life of caffeine is prolonged during the second and third trimesters of pregnancy and maternal and fetal exposure is also influenced by maternal smoking or drinking (Brent 2011; Koren 2000). Current guidelines recommend limiting caffeine intake from all sources to &le;200 mg/day (ACOG 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057048\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apnea of prematurity: Heart rate, number and severity of apnea spells, serum caffeine concentration (as appropriate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stimulant: Insomnia, tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057052\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic: Apnea of prematurity: 8 to 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potentially toxic: &gt;20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;50 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143980\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility); prevention of apnea may occur by competitive inhibition of adenosine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143995\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 0.8 to 0.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;9 months to Adults: 0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 17% (children) to 36% (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via demethylation by CYP1A2. <b>Note:</b> In neonates, interconversion between caffeine and theophylline has been reported (caffeine levels are ~25% of measured theophylline after theophylline administration and ~3% to 8% of caffeine would be expected to be converted to theophylline)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 72 to 96 hours (range: 40 to 230 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;9 months and Adults: 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Within 30 minutes to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &le;1 month: 86% excreted unchanged in urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;1 month and Adults: In urine, as metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 8.9 mL/hour/kg (range: 2.5 to 17)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 94 mL/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11331429\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 10 mg/mL oral solution of caffeine (as citrate) may be prepared from 10 g citrated caffeine powder combined with 10 g citric acid USP and dissolved in 1000 mL distilled water. Label &ldquo;shake well&rdquo;. Stable for 3 months at room temperature (Nahata, 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 20 mg/mL oral solution of caffeine (as citrate) may be made from 10 g citrated caffeine powder and dissolved in 250 mL sterile water for irrigation. Stir solution until completely clear, then add a 2:1 mixture of simple syrup and cherry syrup in sufficient quantity to make 500 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 90 days (Eisenberg, 1984).</p>\n    <div class=\"reference\">Eisenberg MG and Kang N, &quot;Stability of Citrated Caffeine Solutions for Injectable and Enteral Use,&quot; <i>Am J Hosp Pharm</i>, 1984, 41(11):2405-6.<span class=\"pubmed-id\">6507449</span></div>\r\n\n    <div class=\"reference\">Nahata MC and Pai VB, <i>Pediatric Drug Formulations</i>, 6th ed, Cincinnati, OH: Harvey Whitney Books Co, 2014.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323030\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cafcit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine Citrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $34.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine Citrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caffeine-Sodium Benzoate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125-125 mg/mL (2 mL): $21.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Caffeine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (16): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (No Doz Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $6.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038545\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cafcit (VN);</li>\n      <li>Cafnea (AU);</li>\n      <li>Coffeinum Natrium Benzoicum (PL);</li>\n      <li>Kofex (PL);</li>\n      <li>NeoCaf (KR);</li>\n      <li>Peyona (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Committee Opinion No. 462: Moderate Caffeine Consumption During Pregnancy,&quot; <i>Obstet Gynecol</i>, 2010, 116(2 Pt 1):467-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/20664420/pubmed\" target=\"_blank\" id=\"20664420\">20664420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Regent. Product Safety Bulletin. Important Drug Administration Information: Caffeine and Sodium Benzoate Injection, USP, 250 mg/mL (125 mg/mL Caffeine) 2 mL Single Dose Vials. July 18, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlin CM Jr, &quot;Excretion of Methylxanthines in Human Milk,&quot; <i>Semin Perinatol</i>, 1981, 5(4):389-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/7302615/pubmed\" target=\"_blank\" id=\"7302615\">7302615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(3):195-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/12608884 /pubmed\" target=\"_blank\" id=\"12608884 \">12608884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent RL, Christian MS, Diener RM. Evaluation of the reproductive and developmental risks of caffeine. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2011;92(2):152-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/21370398 /pubmed\" target=\"_blank\" id=\"21370398 \">21370398 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cafcit injection (caffeine) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caffeine and sodium bonzoate injection [prescribing information]. Shirley, NY: American Regent, Inc; September 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caffeine citrate injection, oral solution (caffeine) [prescribing information]. Lenoir NC: Exela Pharma Sciences; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choi A, Laurito CE, Cunningham FE. Pharmacologic management of postdural puncture headache. <i>Ann Pharmacother</i>. 1996;30(7-8):831-839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/8826568/pubmed\" target=\"_blank\" id=\"8826568\">8826568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erenberg A, Leff RD, Haack DG, et al, &ldquo;Caffeine Citrate for the Treatment of Apnea of Prematurity: A Double-Blind, Placebo-Controlled Study,&rdquo; <i>Pharmacotherapy</i>, 2000, 20(6):644-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/10853619/pubmed\" target=\"_blank\" id=\"10853619\">10853619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gray PH, Flenady VJ, Charles BG, Steer PA; Caffeine Collaborative Study Group. Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour. <i>J Paediatr Child Health</i>. 2011;47(4):167-172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/21244548/pubmed\" target=\"_blank\" id=\"21244548\">21244548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. <i>Ann Epidemiol</i>. 2005;15(6):460-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/15967394 /pubmed\" target=\"_blank\" id=\"15967394 \">15967394 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hildebrandt R and Gundert-Remy U, &quot;Lack of Pharmacological Active Saliva Levels of Caffeine in Breast-Fed Infants,&quot; <i>Pediatr Pharmacol</i>, 1983, 3(3-4):237-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/6677875/pubmed\" target=\"_blank\" id=\"6677875\">6677875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. <i>Cochrane Database Syst Rev</i>. 2013;2:CD006965.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/23450573 /pubmed\" target=\"_blank\" id=\"23450573 \">23450573 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jarvis AP, Greenawalt JW, Fagraeus L. Intravenous caffeine for postdural puncture headache. <i>Anesth Analg</i>. 1986;65(3):316-317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/3954102/pubmed\" target=\"_blank\" id=\"3954102\">3954102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, &ldquo;Caffeine During Pregnancy? In Moderation,&rdquo; <i>Can Fam Physician</i>, 2000, 46(4):801-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/10790810/pubmed\" target=\"_blank\" id=\"10790810\">10790810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kriter KE and Blanchard J, &ldquo;Management of Apnea in Infants,&rdquo; <i>Clin Pharm</i>, 1989, 8(8):577-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/2670399/pubmed\" target=\"_blank\" id=\"2670399\">2670399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchand S, Li J, Charest J. Effects of caffeine on analgesia from transcutaneous electrical nerve stimulation. <i>N Engl J Med</i>. 1995;333(5):325-326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/7596392/pubmed\" target=\"_blank\" id=\"7596392\">7596392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;n I, L&oacute;pez-V&iacute;lchez MA, Mur A, et al, &quot;Neonatal Withdrawal Syndrome After Chronic Maternal Drinking of Mate,&quot; <i>Ther Drug Monit</i>, 2007, 29(1):127-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/17304161/pubmed\" target=\"_blank\" id=\"17304161\">17304161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maximum Strength Stay Awake tablet (caffeine) [prescribing information]. Pleasanton, CA: Safeway Inc; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson C, Neil JJ, Tjoeng TH, Pineda R, Inder TE. A pilot randomized trial of high-dose caffeine therapy in preterm infants. <i>Pediatr Res</i>. 2015;78(2):198-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/25856169/pubmed\" target=\"_blank\" id=\"25856169\">25856169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohammed S, Nour I, Shabaan AE, Shouman B, Abdel-Hady H, Nasef N. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. <i>Eur J Pediatr</i>. 2015;174(7):949-956.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/25644724/pubmed\" target=\"_blank\" id=\"25644724\">25644724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nodoz Maximum Strength Alertness Aid tablet (caffeine) [prescribing information]. Parsippany, NJ: Novartis Consumer Health, Inc; December 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryu JE, &quot;Caffeine in Human Milk and in Serum of Breast-Fed Infants,&quot; <i>Dev Pharmacol Ther</i>, 1985a, 8(6):329-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/4075932/pubmed\" target=\"_blank\" id=\"4075932\">4075932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryu JE, &quot;Effect of Maternal Caffeine Consumption on Heart Rate and Sleep Time of Breast-Fed Infants,&quot; <i>Dev Pharmacol Ther</i>, 1985b, 8(6):355-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/4075934/pubmed\" target=\"_blank\" id=\"4075934\">4075934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt B, Roberts RS, Davis P, et al, &quot;Caffeine Therapy for Apnea of Prematurity,&quot; <i>N Engl J Med</i>, 2006, 354(20):2112-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/16707748/pubmed\" target=\"_blank\" id=\"16707748\">16707748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt B, Roberts RS, Davis P, et al, &quot;Long-Term Effects of Caffeine Therapy for Apnea of Prematurity,&quot; <i>N Engl J Med</i>, 2007, 357(19):1893-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/17989382/pubmed\" target=\"_blank\" id=\"17989382\">17989382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stay Awake tablet (caffeine) [prescribing information]. Hauppauge, NY: LNK International, Inc; January 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/17989382/pubmed\" target=\"_blank\" id=\"17989382\">17989382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steer P, Flenady V, Shearman A, et al, &quot;High Dose Caffeine Citrate for Extubation of Preterm Infants: A Randomised Controlled Trial,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2004, 89(6):F499-503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/15499141/pubmed\" target=\"_blank\" id=\"15499141\">15499141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesoulis ZA, McPherson C, Neil JJ, Mathur AM, Inder TE. Early high-dose caffeine increases seizure burden in extremely preterm neonates: a preliminary study. <i>J Caffeine Res</i>. 2016;6(3):101-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caffeine-pediatric-drug-information/abstract-text/27679737/pubmed\" target=\"_blank\" id=\"27679737\">27679737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vivarin tablet (caffeine) [prescribing information]. Atlanta, GA: Meda Consumer Healthcare Inc; May, 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13360 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F144010\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057049\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442160\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057043\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143990\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F143978\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057054\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F144007\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057053\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144035\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143996\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143981\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855220\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F144025\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143985\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F143987\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F143998\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057048\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1057052\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143980\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F143995\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11331429\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323030\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038545\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13360|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=caffeine-drug-information\" class=\"drug drug_general\">Caffeine: Drug information</a></li><li><a href=\"topic.htm?path=caffeine-patient-drug-information\" class=\"drug drug_patient\">Caffeine: Patient drug information</a></li></ul></div></div>","javascript":null}